Fundz
An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →

InMed Pharmaceuticals to merge with Mentari Therapeutics

PUBLIC · INMSep 18, 2026•about 3 hours ago

Acquiring Company

InMed Pharmaceuticals

Acquired Company

Mentari Therapeutics

VancouverSan FranciscoHealthcareBiotechnologyHealth CareTherapeutics

Description

InMed Pharmaceuticals has announced a merger with Mentari Therapeutics as part of their previously disclosed Agreement and Plan of Merger and Reorganization. The merger is expected to close in the fourth quarter of 2026, subject to shareholder approval. Upon completion, the combined company anticipates significant financial proceeds to meet Nasdaq's listing requirements. This strategic merger aims to strengthen InMed's position in the pharmaceutical market.

Company Information

Company

InMed Pharmaceuticals

Location

815 W. HASTINGS STREET

Vancouver, British Columbia, Canada

About

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com. Nasdaq: INM

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment InMed Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015
Predictive Intelligence
Strategic

ML-powered predictions for InMed Pharmaceuticals's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Mentari Therapeutics?

Mentari Therapeutics was acquired by InMed Pharmaceuticals, based in Vancouver. The deal was reported on September 18, 2026. InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. InMed Pharmaceuticals is publicly traded (INM) and operates in Healthcare.

When did InMed Pharmaceuticals acquire Mentari Therapeutics?

InMed Pharmaceuticals's acquisition of Mentari Therapeutics was reported on September 18, 2026. InMed Pharmaceuticals has announced a merger with Mentari Therapeutics as part of their previously disclosed Agreement and Plan of Merger and Reorganization. The merger is expected to close in the fourth quarter of 2026, subject to shareholder approval. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Mentari Therapeutics do?

Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine to deliver freedom from this debilitating and undertreated neurological condition. It is privately held, operating in Biotechnology, and is based in San Francisco.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.